Net profit of Torrent Pharmaceuticals rose 26.24% to Rs 635.00 crore in the quarter ended December 2025 as against Rs 503.00 crore during the previous quarter ended December 2024. Sales rose 17.70% to Rs 3251.00 crore in the quarter ended December 2025 as against Rs 2762.00 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales3251.002762.00 18 OPM %33.4733.09 - PBDT1030.00890.00 16 PBT824.00691.00 19 NP635.00503.00 26 Powered by Capital Market - Live News

Torrent Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 13 February 2026, inter alia, have recommended the interim dividend of Rs 29 per equity Share (i.e. 580%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Torrent Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 February 2026.Powered by Capital Market - Live News

Torrent Pharmaceuticals announced that the USFDA inspected its Dahej manufacturing unit from 19 January 2026 to 23 January 2026. The inspection concluded with Zero observations. Powered by Capital Market - Live News

Torrent Pharma has approved the issuance of Secured, Rated, Listed, Redeemable Non-Convertible Debentures (NCDs) aggregating upto Rs 12,500 crore in one or more tranches on private placement basis.Powered by Capital Market - Live News